Mordwinkin Nicholas Michael 4

4 · Kezar Life Sciences, Inc. · Filed Jul 26, 2023

Form 4

Period: 2023-07-24

Chief Business Officer

Transactions

Award
Employee Stock Option (right to buy)
2023-07-24+100,000→ 100,000 total
Exercise: $2.28Exp: 2033-07-23→ Common Stock (100,000 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−185,000→ 0 total
Exercise: $6.84Exp: 2033-01-07→ Common Stock (185,000 underlying)
Award
Employee Stock Option (right to buy)
2023-07-24+185,000→ 185,000 total
Exercise: $2.28Exp: 2033-01-07→ Common Stock (185,000 underlying)

Footnotes (3)

[F1]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.
[F2]On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
[F3]Twenty-five percent (25%) of the shares subject to the option shall vest on July 24, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such vesting date.

Documents

1 file